Parkinson's Blog

A new study has achieved near-perfect accuracy in detecting Parkinson’s disease by analyzing brain responses to emotional stimuli using EEG and AI.

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson’s disease with near-perfect accuracy, simply by analyzing brain responses to emotional situations like watching video clips or images.

The encounter between the A-list actress and veteran interviewer was famously awkward.

Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial for its Parkinson’s medication. Biotech firms live and die on the success of the medications they develop and clinical testing …

Students work on their thesis for weeks, months, sometimes years. Once completed, their work is often relegated to a dusty drawer. The Thesis Tales column is devoted to highlighting student research. In episode 3: Femke Aminetzah (21, Bachelor’s in Artificial Intelligence) investigated the best way to reduce motor symptoms in parkinson’s patients using AI.

Nancy Schexnaider, a hospice social worker from Vermilion Parish, shares why her Parkinson’s diagnosis in 2022 was, “the best thing that ever happened to her.”

University Hospitals and Cleveland Clinic published a peer-reviewed article this month detailing ways to reduce preventable harm during Parkinson’s patients’ hospital stays.

Wrexham player ratings vs Crewe 1️⃣-🔟

Wearable sensor data combined with machine learning predicts fall risk in Parkinson’s patients, enhancing preventive care and clinical outcomes over five years.

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson’s disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea